KR102533646B1 - 4-원 헤테로시클릭 아미드를 포함하는 jak 저해제 - Google Patents

4-원 헤테로시클릭 아미드를 포함하는 jak 저해제 Download PDF

Info

Publication number
KR102533646B1
KR102533646B1 KR1020197029543A KR20197029543A KR102533646B1 KR 102533646 B1 KR102533646 B1 KR 102533646B1 KR 1020197029543 A KR1020197029543 A KR 1020197029543A KR 20197029543 A KR20197029543 A KR 20197029543A KR 102533646 B1 KR102533646 B1 KR 102533646B1
Authority
KR
South Korea
Prior art keywords
compound
lung
disease
ethyl
pneumonia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197029543A
Other languages
English (en)
Korean (ko)
Other versions
KR20190127796A (ko
Inventor
폴 알. 파데리
개리 이.엘. 브랜트
카메론 스미스
스티븐 디.이. 설리반
오르덴 로리 진 반
멜라니 에이. 클라인셰크
글렌 디. 크레이터
Original Assignee
세라밴스 바이오파마 알앤디 아이피, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 filed Critical 세라밴스 바이오파마 알앤디 아이피, 엘엘씨
Publication of KR20190127796A publication Critical patent/KR20190127796A/ko
Application granted granted Critical
Publication of KR102533646B1 publication Critical patent/KR102533646B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
KR1020197029543A 2017-03-09 2018-03-08 4-원 헤테로시클릭 아미드를 포함하는 jak 저해제 Active KR102533646B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469073P 2017-03-09 2017-03-09
US62/469,073 2017-03-09
PCT/US2018/021489 WO2018165392A1 (en) 2017-03-09 2018-03-08 Jak inhibitors containing a 4-membered heterocyclic amide

Publications (2)

Publication Number Publication Date
KR20190127796A KR20190127796A (ko) 2019-11-13
KR102533646B1 true KR102533646B1 (ko) 2023-05-17

Family

ID=61683956

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197029543A Active KR102533646B1 (ko) 2017-03-09 2018-03-08 4-원 헤테로시클릭 아미드를 포함하는 jak 저해제
KR1020197029560A Active KR102526764B1 (ko) 2017-03-09 2018-03-08 융합된 이미다조-피페리딘 jak 저해제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197029560A Active KR102526764B1 (ko) 2017-03-09 2018-03-08 융합된 이미다조-피페리딘 jak 저해제

Country Status (20)

Country Link
US (10) US10196393B2 (https=)
EP (2) EP3592743A1 (https=)
JP (2) JP7134990B2 (https=)
KR (2) KR102533646B1 (https=)
CN (2) CN110382498B (https=)
AR (2) AR111242A1 (https=)
AU (2) AU2018231035B2 (https=)
BR (2) BR112019018648A2 (https=)
CA (1) CA2997772A1 (https=)
DK (1) DK3592742T3 (https=)
EA (2) EA037261B1 (https=)
ES (1) ES2882186T3 (https=)
IL (2) IL268679B (https=)
MX (2) MX388749B (https=)
PH (2) PH12019501941A1 (https=)
PT (1) PT3592742T (https=)
SG (2) SG11201907544VA (https=)
TW (2) TWI779016B (https=)
WO (2) WO2018165395A1 (https=)
ZA (2) ZA201905585B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1252685A1 (zh) 2015-11-03 2019-05-31 Theravance Biopharma R&D Ip, Llc 用於治疗呼吸疾病的jak激酶抑制剂化合物
US10556901B2 (en) * 2015-11-03 2020-02-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as Janus kinase inhibitors
BR112019018648A2 (pt) 2017-03-09 2020-06-16 Theravance Biopharma R&D Ip, Llc Inibidores de jak contendo uma amida heterocíclica com 4 membros
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
US10406148B2 (en) 2017-05-01 2019-09-10 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
PT3837258T (pt) 2018-09-04 2024-06-20 Theravance Biopharma R&D Ip Llc Amidas de dimetil amino azetidina como inibidores de jak
WO2020051139A1 (en) * 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as jak inhibitors
CA3108848A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
MX2021004582A (es) 2018-10-29 2021-06-15 Theravance Biopharma R&D Ip Llc Compuesto 2-azabiciclo hexano inhibidor de jak.
FI3932919T3 (fi) 2019-02-25 2024-08-30 Henan Medinno Pharmaceutical Tech Co Ltd Jak-inhibiittoriyhdiste ja sen käyttö
MA55201A (fr) 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
CN114901659A (zh) * 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
WO2021136345A1 (zh) * 2019-12-30 2021-07-08 路良 Jak抑制剂化合物及其用途
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022178215A1 (en) * 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
TW202317550A (zh) 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
JP7644873B2 (ja) * 2021-12-17 2025-03-12 デウン ファーマシューティカル カンパニー リミテッド （２Ｒ，３Ｓ）－２－（３－（４，５－ジクロロ－１Ｈ－ベンゾ［ｄ］イミダゾール－１－イル）プロピル）ピペリジン－３－オールの新規な酸付加塩および結晶形
CN117658852B (zh) * 2023-11-15 2026-03-24 西北工业大学 取代苯氧乙酰肼类化合物及其制备方法和作为stat3的抗炎抑制剂的应用
WO2025157904A1 (en) * 2024-01-24 2025-07-31 Kiox Pharmaceuticals Aps Inhalable formulations of ruxolitinib, methods of manufacture and uses thereof
CN118903009B (zh) * 2024-10-11 2025-01-21 江苏长泰药业股份有限公司 一种调节呼吸道微生态的丙酮酸钠气雾剂及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013014567A1 (en) 2011-07-27 2013-01-31 Pfizer Limited Indazoles
WO2017077288A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
JP4836788B2 (ja) 2003-07-23 2011-12-14 エグゼリクシス， インコーポレイテッド 未分化リンパ腫キナーゼ変調因子及びその使用法
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
EP2414340A1 (en) 2009-04-03 2012-02-08 Dainippon Sumitomo Pharma Co., Ltd. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
EP2515655B1 (en) 2009-12-21 2015-08-05 Samumed, LLC 1h-pyrazolo[3,4-beta]pyridines and therapeutic uses thereof
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
EP2771340B1 (en) 2011-10-25 2016-04-13 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MX368464B (es) 2013-12-05 2019-10-02 Pfizer Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo.
CR20160525A (es) 2014-05-14 2016-12-20 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
EP3712152B1 (en) 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
HK1252685A1 (zh) 2015-11-03 2019-05-31 Theravance Biopharma R&D Ip, Llc 用於治疗呼吸疾病的jak激酶抑制剂化合物
BR112019018648A2 (pt) 2017-03-09 2020-06-16 Theravance Biopharma R&D Ip, Llc Inibidores de jak contendo uma amida heterocíclica com 4 membros
US10406148B2 (en) 2017-05-01 2019-09-10 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CN110603255B (zh) 2017-05-01 2023-02-10 施万生物制药研发Ip有限责任公司 Jak抑制剂化合物的结晶型式
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
WO2020051139A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc 5 to 7 membered heterocyclic amides as jak inhibitors
CA3108848A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
PT3837258T (pt) 2018-09-04 2024-06-20 Theravance Biopharma R&D Ip Llc Amidas de dimetil amino azetidina como inibidores de jak

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013014567A1 (en) 2011-07-27 2013-01-31 Pfizer Limited Indazoles
JP2014522865A (ja) 2011-07-27 2014-09-08 ファイザー・リミテッド インダゾール
WO2017077288A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Medicinal Chemistry, vol.60, no.2, pp.767-786

Also Published As

Publication number Publication date
TWI754019B (zh) 2022-02-01
TW201840560A (zh) 2018-11-16
JP2020510010A (ja) 2020-04-02
JP7134990B2 (ja) 2022-09-12
US20180258088A1 (en) 2018-09-13
ES2882186T3 (es) 2021-12-01
EA201992128A1 (ru) 2020-01-29
US10519153B2 (en) 2019-12-31
KR20190127798A (ko) 2019-11-13
MX2019010539A (es) 2019-10-21
US10208040B2 (en) 2019-02-19
TW201837037A (zh) 2018-10-16
US11254669B2 (en) 2022-02-22
US20230063643A1 (en) 2023-03-02
ZA201905618B (en) 2021-05-26
MX388749B (es) 2025-03-11
BR112019018649A2 (pt) 2020-04-07
EA201992126A1 (ru) 2020-02-05
MX388750B (es) 2025-03-20
KR20190127796A (ko) 2019-11-13
US20190127371A1 (en) 2019-05-02
US10392386B2 (en) 2019-08-27
MX2019010541A (es) 2019-10-21
WO2018165392A1 (en) 2018-09-13
IL268689B2 (en) 2023-02-01
ZA201905585B (en) 2020-05-27
TWI779016B (zh) 2022-10-01
AU2018231035A1 (en) 2019-09-05
DK3592742T3 (da) 2021-08-09
BR112019018648A2 (pt) 2020-06-16
AR111241A1 (es) 2019-06-19
AU2018231032A8 (en) 2019-10-17
CN110382498B (zh) 2022-07-12
US20200216447A1 (en) 2020-07-09
US10954237B2 (en) 2021-03-23
CA2997772A1 (en) 2018-09-09
IL268679A (en) 2019-10-31
CN110461839A (zh) 2019-11-15
US10196393B2 (en) 2019-02-05
US11667637B2 (en) 2023-06-06
AU2018231032A1 (en) 2019-09-05
US10550118B2 (en) 2020-02-04
EP3592743A1 (en) 2020-01-15
PT3592742T (pt) 2021-07-30
WO2018165395A1 (en) 2018-09-13
IL268689B (en) 2022-10-01
JP2020510015A (ja) 2020-04-02
US20190337945A1 (en) 2019-11-07
US11453668B2 (en) 2022-09-27
EP3592742B1 (en) 2021-05-19
AU2018231035B2 (en) 2021-09-09
EP3592742A1 (en) 2020-01-15
AR111242A1 (es) 2019-06-19
KR102526764B1 (ko) 2023-04-27
US11878977B2 (en) 2024-01-23
PH12019501941A1 (en) 2020-07-06
SG11201907544VA (en) 2019-09-27
IL268689A (en) 2019-10-31
US20180258087A1 (en) 2018-09-13
SG11201907840RA (en) 2019-09-27
US20190119275A1 (en) 2019-04-25
IL268679B (en) 2021-10-31
NZ756823A (en) 2021-04-30
US20210269436A1 (en) 2021-09-02
CN110461839B (zh) 2022-08-23
AU2018231032B2 (en) 2021-08-19
PH12019501985A1 (en) 2020-10-05
US20200181141A1 (en) 2020-06-11
EA037261B1 (ru) 2021-03-01
US20220289737A1 (en) 2022-09-15
CN110382498A (zh) 2019-10-25
JP6974487B2 (ja) 2021-12-01
EA037748B1 (ru) 2021-05-18

Similar Documents

Publication Publication Date Title
US11878977B2 (en) JAK inhibitors containing a 4-membered heterocyclic amide
US11634419B2 (en) Dimethyl amino azetidine amides as JAK inhibitors
US11713315B2 (en) 5 to 7 membered heterocyclic amides as JAK inhibitors
NZ756823B2 (en) Jak inhibitors containing a 4-membered heterocyclic amide

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601